Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2
This new publication from Novartis in collaboration with public health and academic researchers in Finland and the US adds to the evidence-base on how narcolepsy might have been triggered in genetically susceptible individuals.
European Medicines Agency (EMA) 2009 Influenza Pandemic Evaluation
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.
Ninth Update of EMA Pharmacovigilance Report, 3 Feb 2010
This update, the ninth in the series published by the European Medicines Agency (EMA) provides a summary of the progress of vaccination with pandemic vaccines in Europe with particular emphasis on pharmacovigilance and safety.
ECDC – VAESCO investigation into narcolepsy
This initiative was taken following the indication of a potential association between the 2009 pandemic influenza A(H1N1) monvalent vaccine and the occurrence of narcolepsy following reports, especially in children from Finland and Sweden.
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in Europe
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
Reports of cases of narcolepsy and cataplexy in children and adolescents in Finland, Iceland, and Sweden
In February 2011, ECDC published a report concerning a rise in narcolepsy in children and adolescents in some northern countries.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescents
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.